JP2002506463A - 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法 - Google Patents

利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法

Info

Publication number
JP2002506463A
JP2002506463A JP55433199A JP55433199A JP2002506463A JP 2002506463 A JP2002506463 A JP 2002506463A JP 55433199 A JP55433199 A JP 55433199A JP 55433199 A JP55433199 A JP 55433199A JP 2002506463 A JP2002506463 A JP 2002506463A
Authority
JP
Japan
Prior art keywords
adenosine
diuretic
antagonist
furosemide
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP55433199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506463A5 (cg-RX-API-DMAC7.html
Inventor
ベックマン，エバン
スミッツ，グレン
Original Assignee
バイオジェン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン，インコーポレイテッド filed Critical バイオジェン，インコーポレイテッド
Publication of JP2002506463A publication Critical patent/JP2002506463A/ja
Publication of JP2002506463A5 publication Critical patent/JP2002506463A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP55433199A 1998-04-24 1999-04-23 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法 Ceased JP2002506463A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8302298P 1998-04-24 1998-04-24
US60/083,022 1998-04-24
US8363898P 1998-04-30 1998-04-30
US60/083,638 1998-04-30
PCT/US1999/008879 WO1999055339A1 (en) 1998-04-24 1999-04-23 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009014811A Division JP2009102399A (ja) 1998-04-24 2009-01-26 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法

Publications (2)

Publication Number Publication Date
JP2002506463A true JP2002506463A (ja) 2002-02-26
JP2002506463A5 JP2002506463A5 (cg-RX-API-DMAC7.html) 2006-09-21

Family

ID=26768857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP55433199A Ceased JP2002506463A (ja) 1998-04-24 1999-04-23 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
JP2009014811A Pending JP2009102399A (ja) 1998-04-24 2009-01-26 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009014811A Pending JP2009102399A (ja) 1998-04-24 2009-01-26 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法

Country Status (8)

Country Link
EP (1) EP0994711B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002506463A (cg-RX-API-DMAC7.html)
AT (1) ATE252905T1 (cg-RX-API-DMAC7.html)
AU (1) AU3757999A (cg-RX-API-DMAC7.html)
CA (1) CA2295101C (cg-RX-API-DMAC7.html)
DE (1) DE69912375T2 (cg-RX-API-DMAC7.html)
ES (1) ES2211079T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999055339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
NZ527917A (en) 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
EP1932529A1 (en) * 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPH01254664A (ja) * 1988-04-04 1989-10-11 Daiichi Rajio Isotope Kenkyusho:Kk 新規ピリジニウム−テクネチウム９９ｍ錯体
JPH05502240A (ja) * 1990-08-17 1993-04-22 バクスター、インターナショナル、インコーポレイテッド ヘモグロビンオリゴマーに基づく組成物及びその製造方法
WO1996027386A1 (en) * 1995-03-06 1996-09-12 Houghten Pharmaceuticals, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB998971A (en) * 1961-09-21 1965-07-21 Societé Civile Nova Improvements in or relating to medicines having a diuretic action
DE3305935C2 (de) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kaliumneutrales Saluretikum mit antihypertensiver Wirkung
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPH01254664A (ja) * 1988-04-04 1989-10-11 Daiichi Rajio Isotope Kenkyusho:Kk 新規ピリジニウム−テクネチウム９９ｍ錯体
JPH05502240A (ja) * 1990-08-17 1993-04-22 バクスター、インターナショナル、インコーポレイテッド ヘモグロビンオリゴマーに基づく組成物及びその製造方法
WO1996027386A1 (en) * 1995-03-06 1996-09-12 Houghten Pharmaceuticals, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6008042652, Ｊ． Ｍｅｄ． Ｃｈｅｍ．, 19970606, Ｖｏｌ．４０， Ｎｏ．１２, ｐ．１７７３−１７７８ *
JPN6008042656, Ｗｅｓｔ Ｊ． Ｍｅｄ．, 199010, Ｖｏｌ．１５３，Ｎｏ．４, ｐ．４０６−４１４ *
JPN6008042659, Ｈｅａｒｔ, 199604, Ｖｏｌ．７５，Ｎｏ．４, ｐ．３４９−３５１ *
JPN6008042661, ＣＭＡＪ, 19880415, Ｖｏｌ．１３８，ＮＯ．８, ｐ．６８９−６９３ *

Also Published As

Publication number Publication date
EP0994711A1 (en) 2000-04-26
CA2295101A1 (en) 1999-11-04
DE69912375T2 (de) 2004-08-19
AU3757999A (en) 1999-11-16
ES2211079T3 (es) 2004-07-01
JP2009102399A (ja) 2009-05-14
ATE252905T1 (de) 2003-11-15
DE69912375D1 (de) 2003-12-04
WO1999055339A1 (en) 1999-11-04
WO1999055339A8 (en) 1999-12-29
EP0994711B1 (en) 2003-10-29
CA2295101C (en) 2009-06-30

Similar Documents

Publication Publication Date Title
PT2086535E (pt) Antagonista do receptor de angiotensina ii para o tratamento de doenças sistémicas em gatos
US6818647B2 (en) Method and composition for restoring diuretic and renal function
JP2009102399A (ja) 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
JP2009539996A (ja) 腎機能障害を持つ個体における利尿改善方法
Kennefick et al. Hypertension and renal injury in experimental polycystic kidney disease
US20050038017A1 (en) Method and composition for restoring diuretic and renal function
KR20060004959A (ko) 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
JP7745086B2 (ja) ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
US20160184319A1 (en) Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
EP2157089A1 (en) The therapeutic uses of imidazol-5-carboxylic acid derivatives
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
JP2001507006A (ja) 糖尿病性血管機能不全の予防のための薬剤の製造へのｃｏｍｔ阻害剤の使用
EP1386609A1 (en) Adenosine A1 receptor antagonist containing composition and method for restoring diuretic and renal function
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
Yao et al. Effect of the selective adenosine A1-receptor antagonist KW-3902 on lipopolysaccharide-induced reductions in urine volume and renal blood flow in anesthetized dogs
JP2548223B2 (ja) 腎臓疾患治療剤
CN120093759B (zh) 一种预防或治疗动脉硬化的药物组合物及其应用
Wolff et al. Renal effects of BG9719, a specific A1 adenosine receptor antagonist, in congestive heart failure
CA1310908C (en) Treating agents for renal diseases
JP2002138052A (ja) 掻痒治療薬
JPH09502188A (ja) 血管拡張剤による肝臓病および同様の症状の治療方法
Penner et al. Selective Alpha‐1 Adrenoceptor Blockade and Renal Sodium Handling in Humans
HU206612B (en) Process for producing antihypertenzive combinative composition
Van Dyke et al. Drugs used in gout
KR20010013014A (ko) 고립성 수축기 고혈압증의 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060418

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060418

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100506

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20100928